陈世益;胡宁;贾岩波;李箭;李棋;尚西亮;

• 1:中华医学会运动医疗分会
• 2:中国医师协会骨科医师分会运动医学学组
• 3:中国医师协会骨科医师分会关节镜学组
• 4:复旦大学附属华山医院

摘要(Abstract)：

<正>1 背景骨关节炎(osteoarthritis,OA)是由多种因素引起的以关节软骨磨损、皲裂、溃疡、脱失,关节软骨下骨及周围骨反应、滑膜炎性反应、关节周围肌肉萎缩,关节疼痛、关节功能下降的退行性关节病,易发生于中老年人群,发病率高,65岁以上膝痛人群有超过50%为OA患者,75岁以上膝痛人群中的OA患病率超过80%[1,2]。OA病因尚不完全明确,其发生与年龄、肥胖、炎症、创伤及遗传因素等有关。OA的病理特点为关节软骨变性破坏、

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 陈世益;胡宁;贾岩波;李箭;李棋;尚西亮;

参考文献(References)：

• [1]TANG X,WANG S,ZHAN S,et al.The Prevalence of Symptomatic Knee Osteoarthritis in China:Results From the China Health and Retirement Longitudinal Study[J].Arthritis Rheumatol,2016,68(3):648-653.
• [2]LESPASIO M J,PIUZZI N S,HUSNI M E,et al.Knee Osteoarthritis:A Primer[J].Perm J,2017,21:16-183.
• [3]李娟.骨关节炎的病理与发病因素[J].医药前沿，2017，7(24)：216-217.
• [4]HUANG Z,CHEN J,MA J,et al.Effectiveness of low-level laser therapy in patients with knee osteoarthritis:a systematic review and meta-analysis[J].Osteoarthritis Cartilage,2015,23(9):1437-1444.
• [5]HUANG Z,MA J,CHERT J,et al.The effectiveness of low-level laser therapy for nonspeeificchronic low back pain:a syste-matic review and meta-analysis[J].Arthritis Res Ther,2015,17:360.
• [6]中华医学会骨科学分会关节外科学组.骨关节炎诊疗指南(2018年版)[J].中华骨科杂志，2018，38(12)：705-715.
• [7]ZHANG W,DOHERTY M,LEEB B F,et al.EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis:report of a task force of ESCISIT[J].Ann Rheum Dis,2009,68(1):8-17.
• [8]ZHANG W,DOHERTY M,PEAT G,et al.EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis[J].Ann Rheum Dis,2010,69(3):483-489.
• [9]中华医学会运动医疗分会，外用NSAIDs疼痛治疗中国专家委员会.外用非甾体抗炎药治疗肌肉骨骼系统疼痛的中国专家共识[J].中国医学前沿杂志(电子版)，2016，8(7)：24-27.
• [10]MU R,BAO C D,CHEN Z W,et al.Efficacy and safety of loxoprofen hydrogel patch versus loxoprofen tablet in patients with knee osteoarthritis:a randomized controlled non-inferiority trial[J].Clin Rheumatol,2016,35(1):165-173.
• [11]BANNURU R R,OSANI M C,VAYSBROT E E,et al.OARSI guidelines for the non-surgical management of knee,hip,and polyarticular osteoarthritis[J].Osteoarthritis Cartilage,2019,27(11):1578-1589.
• [12]中华医学会骨科学分会关节外科学组.中国骨关节炎疼痛管理临床实践指南(2020年版)[J].中华骨科杂志，2020，40(8)：469-476.
• [13]WANDEL S,JTINI P,TENDAL B,et al.Effects of gluco-samine,chondroitin,or placebo in patients with osteoarthritis of hip or knee:network meta-analysis[J].BMJ,2010,341:c4675.
• [14]KONGTHARVONSKUL J,ANOTHAISINTAWEE T,MCEVOY M,et al.Efficacy and safety of glucosamine,diace-rein,and NSAIDs in osteoarthritis knee:a systematic review and network meta-analysis[J].Eur J Med Res,2015,20:24.
• [15]MCALINDON T E,BANNURU R R,SULLIVAN M C,et al.OARSI guidelines for the non-surgical management of knee osteoarthritis[J].Osteoarthritis Cartilage,2014,22(3):363-388.
• [16]李德龙，阮光峰，丁长海.骨关节炎的骨质疏松亚型及治疗进展[J].中华医学信息导报，2018，33(11)：13.
• [17]RISSER R C,HOCHBERG M C,GAYNOR P J,et al.Responsiveness of the Intermittent and Constant Osteoarthritis Pain (ICOAP) scale in a trial of duloxetine for treatment of osteoarthritis knee pain[J].Osteoarthfitis Cartilage,2013,21(5):691-694.
• [18]HOCHBERG M C,WOHLREICH M,GAYNOR P,et al.Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteo-a-rt-hritis[J].J Rheumatol,2012,39(2):352-358.
• [19]BANNURU R R,NATOV N S,OBADAN I E,et al.Therap-eutic trajeetory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis:a systematic review and meta-analysis[J].Arthritis Rheum,2009,61(12):1704-1711.
• [20]LEUSSINK V I,JUNG S,MERSCHDORF U,et al.High dose methylperdnislone therapy in multiple sclerosis induces apoptosis inperiphearal blood leukocytes[J].Arch Neurol,2001,58(1):91-97.
• [21]梁瑀彤.治疗骨关节炎的糖皮质激素类关节腔注射缓控释制剂研究进展[J].世界最新医学信息文摘，2020，20(35)：30-31.
• [22]张程，董国权，郝满良.糖皮质激素抗炎作用研究进展[J].青海畜牧兽医杂志，2017，47(2)：51-54.
• [23]VAN M M,ARDEN N K,BIRRELL F,et al.The OA Trial Bank:meta-analysis of individual patient data from knee and hip osteoarthritis trials show that patients with severe pain exhibit greater benefit from intra-articular glucocorticoids[J].Osteoarthritis Cartilage,2016,24(7):1143-1152.
• [24]VANDEWEERD J M,ZHAO Y,NISOLLE J F,et al.Effect of eorticosteroids on articular cartilage:have animal studies said everything?[J].Fundam Clin Pharmacol,2015,29(5):427-438.
• [25]刘译汉，王立春，张宏颖，等.动物脂肪干细胞联合双重转化生长因子释放支架修复关节软骨损伤的实验研究[J].中国骨与关节损伤杂志，2012，27(12)：1098-1101.
• [26]中华医学会骨科学分会.骨关节炎诊治指南(2007年版)[J].中华骨科杂志，2007，27(10)：793-796.
• [27]NELSON A E,ALLEN K D,GOLIGHTLY Y M,et al.A systematic review ofrecommendations and guidelines for the management of osteoarthritis:The chronic osteoarthritis management initiative of the U.S.bone andjoint initiative[J].Semin Arthritis Rheum,2014,43(6):701-712.
• [28]OPRENYESZK F,SANCHEZ C,DUBUC J E,et al.Chitosan enriched three-dimensional matrix reduces inflammatory and catabolic mediators production by human chondrocytes[J].PLoS One,2015,10(5):e0128362.
• [29]OPRENYESZK F,CHAUSSON M,MAQUET V,et al.Protective effect of a new biomaterial against the development of experimental osteoarthritis lesions in rabbit:a pilot study evaluating the intra-articular injection of alginate-chitosan beads dispersed in anhydrogel[J].Osteoarthritis Cartilage,2013,21(8):1099-1107.
• [30]中国医师协会骨科医师分会运动医学专业委员会.玻璃酸钠在骨科和运动医学相关疾病中的应用专家共识(2017年修订版)[J].中国医学前沿杂志(电子版)，2017，9(11)：1-8.
• [31]BANNURU R R,VAYSBROT E E,SULLIVAN M C,et al.Relative efficacyof hyaluronie acid in comparison with NSAIDs for knee osteoarthritis:a systematic review and meta-analysis[J].Semin Arthritis Rheum,2014,43(5):593-599.
• [32]ISHIJIMA M,NAKAMURA T,SHIMIZU K,et al.Intra-articular hyaluronic acid injection versus oral non-steroidal anti-inflammatory drug for the treatment of knee osteoarthritis:a multi-center,randomized,open-label,non-inferiority trial[J].Arthritis Res Ther,2014,16(1):R18.
• [33]ZHU Y,YUAN M,MENG H Y,et al.Basic science and clinical application of platelet-rich plasma for cartilage defects and osteoarthritis:a review[J].Osteoarthritis Cartilage,2013,21(11):1627-1637.
• [34]KHATAB S,VAN BUUL G M,KOPS N,et al.Intra-articular Injections of platelet-rich plasma releasate reduce pain and synovial inflammation in a mouse model of osteoarthritis[J].Am J Sports Med,2018,46(4):977-986.
• [35]SMYTH N A,MURAWSKI C D,FORTIER L A,et al.Platelet-rich plasma in the pathologic processes of cartilage:review of basic science evidence[J].Arthroscopy,2013,29(8):1399-1409.
• [36]SHETH U,SIMUNOVIC N,KLEIN G,et al.Efficacy of autologous platelet-rich Plasma use for orthopaedic indications:a meta-analysis[J].J Bone Joint Surg Am,2012,94(4):298-307.
• [37]中国医疗保健国际交流促进会骨科分会.关节腔注射富血小板血浆治疗膝骨关节炎的临床实践指南(2018年版)[J].中华关节外科杂志(电子版)，2018，12(4)：1-5.
• [38]中国医疗保健国际交流促进会骨科分会.富血小板血浆在骨关节外科临床应用专家共识(2018年版)[J].中华关节外科杂志(电子版)，2018，12(5)：596-600.
• [39]葛广勇，赵建宁.白细胞介素-1受体拮抗剂与骨性关节炎的关系[J].医学研究生学报，2007，20(10)：1084-1087.
• [40]张洁，黄烽.骨关节炎的靶向治疗：现状与未来[J].中国药物应用与监测，2005(3)：45-48.
• [41]吴江怡，陈昊，杨柳.骨关节炎的关节腔内注射药物及生物制剂治疗现状[J].骨科临床与研究杂志，2019，4(2)：113-119.
• [42]HOCHBERG M C,ALTMAN R D,APRIL K T,et al.American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand,hip,and knee[J].Arthritis Care Res (Hoboken),2012,64(4):465-474.
• [43]National Clinical Guideline Centre (UK).Osteoarthritis:care and management in adults[M].London:National Institute for Healthand Care Excellence (UK),2014.
• [44]ZHANG W,DOHERTY M,ARDEN N,et al.EULAR evidence based recommendations for the management of hip osteoarthritis:report of a task force of the EULAR Standing Committee for International Clinical Studies Including Terap-eutics (ESCISIT)[J].Ann Rheum Dis,2005,64(5):669-681.
• [45]JORDAN K M,ARDEN N K,DOHERTY M,et al.EULAR Recommendations 2003:an evidence based approach to the management of knee osteoarthritis:report of a Task Force of the Standing Committee for International Clinical Studies Including Terapeutic Trials (ESCISIT)[J].Ann Rheum Dis,2003,62(12):1145-1155.
• [46]COMBE B,LANDEWE R,LUKAS C,et al.EULAR recomm-endations for the management of early arthritis:report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISlT)[J].Ann Rheum Dis,2007,66(1):34-45.
• [47]ZHANG W,MOSKOWITZ R W,NUKI G,et al.OARSI recommendations for the management of hip and knee osteo-arthritis,Part Ⅱ:OARSI evidence-based,expert consensus guid-elines[J].Osteoarthritis Cartilage,2008,16(2):137-162.
• [48]ZHANG W,NUKI G,MOSKOWITZ R W,et al.OARSI recommendations for the management of hip and knee osteoar-th-ritis Part Ⅲ:changes in evidence following systematic cumula-tive update of research published through January 2009[J].Osteoarthritis Cartilage,2010,18(4):476-499.
• [49]CHEN B,ZHAN H,MARSZALEK J,et al.Traditional Chinese Medications for Knee Osteoarthritis Pain:A Meta-Analysis of Randomized Controlled Trials[J].Am J Chin Med,2016,44(4):677-703.
• [50]LI L,LIU H,SHI W,et al.Insights into the Action Mechanisms of Traditional Chinese Medicine in Osteoarthritis[J].Evid Based Complement Ahernat Med,2017,2017:5190986.
• [51]WANG X,WEI S,LIU T,et al.Effectiveness,medication patterns,and adverse events of traditional chinese herbal patches for osteoarthritis:a systematic review[J].Evid Based Complement Ahernat Med,2014,2014:343176.
• [52]TEODORO J S,VARELA A T,ROLO A P,et al.High-fat and obesogenic diets:current and future strategies to fight obesity and diabetes[J].Genes Nutr,2014,9(4):406.
• [53]SCHEEN A J,VAN GAAL L F.Combating the dual burden:therapeutic targeting of common pathways in obesity and type 2 diabetes[J].Lancet Diabetes Endocrinol,2014,2(11):911-922.
• [54]MUNIYAPPA R,KARNE R J,HALL G,et al.Oral glucosa-mine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects[J].Diabetes,2006,55(11):3142-3150.
• [55]OFMAN J J,MACLEAN C H,STRAUS W L,et al.Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs[J].Arthritis Rheum,2003,49(4):508-518.
• [56]TANNENBAUM H,BOMBARDIER C,DAVIS P,et al.An evidence-based approach to prescribing nonsteroidal antiinfl-ammatory drugs.Third Canadian Consensus Conference[J].J Rheumatol,2006,33(1):140-157.
• [57]WOLFE M M,LICHTENSTEIN D R,SINGH G.Gastroint-estinal toxicity of nonsteroidal antiinflammatory drugs[J].N Engl J Med,1999,340(24):1888-1899.
• [58]LANZA F L,CHAN F K,QUIGLEY E M,et al.Guidelines for prevention of NSAID-related ulcer complications[J].Am J Gastroenterol,2009,104(3):728-738.
• [59]KULKARNI K,KARSSIENS T,KUMAR V,et al.Obesity and osteoarthritis[J].Maturitas,2016,89:22-28.
• [60]FRANCISCO V,PéREZ T,PINO J,et al.Biomechanics,obesity,and osteoarthritis.The role of adipokines:When the levee breaks[J].J Orthop Res,2018,36(2):594-604.
• [61]RIOS J L,BOMHOF M R,REIMER R A,et al.Protective effect of prebiotic and exercise intervention on knee health in a rat model of diet-induced obesity[J].Sci Rep,2019,9(1):3893.
• [62]HUSSAIN S M,DAWSON C,WANG Y,et al.Vascular Patho-logy and Osteoarthritis:A Systematic Review[J].J Rheumatol,2020,47(5):748-760.